Edition:
India

People: DBV Technologies SA (DBV.PA)

DBV.PA on Paris Stock Exchange

34.22EUR
9:05pm IST
Change (% chg)

€-0.52 (-1.50%)
Prev Close
€34.74
Open
€35.00
Day's High
€35.48
Day's Low
€34.16
Volume
67,234
Avg. Vol
126,784
52-wk High
€86.64
52-wk Low
€32.88

Sampson, Hugh 

Mr. Hugh A. Sampson, M.D., is an Chief Scientific Officer of the Company. effective on November 1, 2015. Hugh A. Sampson, M.D., is a professor of Pediatrics at the Icahn School of Medicine at Mount Sinai School, N.Y., USA. He is Director of the Jaffe Food Allergy Institute; and Dean of Translational Biomedical Science at The Mount Sinai Medical Center. He received his M.D. from the State University of New York at Buffalo School of Medicine. Dr. Sampson's research interests have focused on food allergic disorders, including work on the immunopathogenic role of food hypersensitivity in atopic dermatitis, the pathogenesis of food-induced anaphylaxis, the characterization of food-induced gastrointestinal hypersensitivities, the characterization of food allergens, and novel immunotherapeutic strategies (recombinant engineered protein, plasmid DNA, peptide, etc.) for treating food allergies. His research has been funded by a number of grants from the National Institutes of Health (NIH) and private foundations. He is the Principal Investigator of the NIH-sponsored Consortium of Food Allergy Research (CoFAR). He is also former President of the American Academy of Allergy Asthma and Immunology (AAAAI).

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --